These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 23894309)
1. Complete genome sequence of the cystic fibrosis pathogen Achromobacter xylosoxidans NH44784-1996 complies with important pathogenic phenotypes. Jakobsen TH; Hansen MA; Jensen PØ; Hansen L; Riber L; Cockburn A; Kolpen M; Rønne Hansen C; Ridderberg W; Eickhardt S; Hansen M; Kerpedjiev P; Alhede M; Qvortrup K; Burmølle M; Moser C; Kühl M; Ciofu O; Givskov M; Sørensen SJ; Høiby N; Bjarnsholt T PLoS One; 2013; 8(7):e68484. PubMed ID: 23894309 [TBL] [Abstract][Full Text] [Related]
2. Genomic insights into intrinsic and acquired drug resistance mechanisms in Achromobacter xylosoxidans. Hu Y; Zhu Y; Ma Y; Liu F; Lu N; Yang X; Luan C; Yi Y; Zhu B Antimicrob Agents Chemother; 2015 Feb; 59(2):1152-61. PubMed ID: 25487802 [TBL] [Abstract][Full Text] [Related]
3. Presence of OXA-type enzymes in Achromobacter insuavis and A. dolens. Traglia G; Papalia M; Almuzara M; Gutkind G; Centrón D; Vay C; Radice M; Ramírez MS Curr Microbiol; 2014 Oct; 69(4):501-6. PubMed ID: 24894902 [TBL] [Abstract][Full Text] [Related]
4. A putative enoyl-CoA hydratase contributes to biofilm formation and the antibiotic tolerance of Cameron LC; Bonis B; Phan CQ; Kent LA; Lee AK; Hunter RC NPJ Biofilms Microbiomes; 2019; 5(1):20. PubMed ID: 31396394 [No Abstract] [Full Text] [Related]
13. Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report. Hoyle N; Zhvaniya P; Balarjishvili N; Bolkvadze D; Nadareishvili L; Nizharadze D; Wittmann J; Rohde C; Kutateladze M Res Microbiol; 2018 Nov; 169(9):540-542. PubMed ID: 29777836 [TBL] [Abstract][Full Text] [Related]
14. Genomic and phylogenetic analysis of multidrug-resistant Achromobacter xylosoxidans ST273 strain MTYH1 co-carrying bla Zhu Z; Xu J; He F J Glob Antimicrob Resist; 2021 Jun; 25():110-113. PubMed ID: 33766786 [TBL] [Abstract][Full Text] [Related]
15. In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis. Mathy V; Grohs P; Compain F J Med Microbiol; 2018 Sep; 67(9):1217-1220. PubMed ID: 30016231 [TBL] [Abstract][Full Text] [Related]
16. Chronic Airway Colonization by Achromobacter xylosoxidans in Cystic Fibrosis Patients Is Not Sustained by Their Domestic Environment. Dupont C; Jumas-Bilak E; Doisy C; Aujoulat F; Chiron R; Marchandin H Appl Environ Microbiol; 2018 Dec; 84(23):. PubMed ID: 30217850 [No Abstract] [Full Text] [Related]
17. First description of an RND-type multidrug efflux pump in Achromobacter xylosoxidans, AxyABM. Bador J; Amoureux L; Duez JM; Drabowicz A; Siebor E; Llanes C; Neuwirth C Antimicrob Agents Chemother; 2011 Oct; 55(10):4912-4. PubMed ID: 21807978 [TBL] [Abstract][Full Text] [Related]